Royalty Pharma
(RPRX) ✕
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
undefined
undefined%
At close: undefined
25.84
0.02%
After-hours Jan 03, 2025, 04:00 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
Revenue | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B | 1.65B |
Cost of Revenue | 560.66M | 5.67M | 23.00M | 88.11M | 1.02B | 135.96M | 33.27M | n/a | n/a |
Gross Profit | 1.79B | 2.23B | 2.27B | 2.03B | 794.93M | 1.66B | 1.56B | 1.88B | 1.65B |
Operating Income | 1.49B | 977.50M | 1.43B | 1.59B | 2.62B | 1.36B | 939.69M | 722.87M | 794.28M |
Interest Income | 72.29M | 78.33M | 53.53M | 28.38M | 22.33M | 24.44M | 6.76M | n/a | n/a |
Pretax Income | 1.70B | 230.06M | 1.24B | 1.70B | 2.46B | 1.52B | 1.34B | 761.89M | 758.71M |
Net Income | 1.13B | 42.83M | 478.75M | 495.20M | 2.35B | 1.38B | 1.21B | 565.91M | 581.43M |
Selling & General & Admin | 249.75M | 227.30M | 182.83M | 182.00M | 103.44M | 61.91M | 106.44M | 69.51M | 121.42M |
Research & Development | 52.00M | 177.11M | 200.08M | 26.00M | 83.04M | 392.61M | 117.87M | 91.02M | 98.38M |
Other Expenses | n/a | 909.91M | 475.84M | 319.00M | -995.40M | -1.52M | -1.62M | -925.80M | -570.18M |
Operating Expenses | 862.40M | 1.31B | 858.75M | 527.00M | -808.92M | 430.45M | 658.24M | 1.09B | 789.98M |
Interest Expense | 187.19M | 187.96M | 166.14M | 157.00M | 268.57M | 279.96M | 247.34M | 238.91M | 224.42M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 862.40M | 1.31B | 858.75M | 527.00M | -808.92M | 430.45M | 658.24M | 1.15B | 858.14M |
Income Tax | n/a | 187.23M | 762.45M | 1.15B | 349.33M | 433.37M | 542.65M | 195.99M | 177.28M |
Shares Outstanding (Basic) | 447.60M | 437.96M | 414.79M | 375.44M | 365.90M | 354.18M | 354.18M | 607.04M | 607.04M |
Shares Outstanding (Diluted) | 602.90M | 437.97M | 414.80M | 375.45M | 365.90M | 354.18M | 354.18M | 607.04M | 607.04M |
EPS (Basic) | 3.41 | 0.10 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
EPS (Diluted) | 2.53 | 0.10 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
EBITDA | 1.89B | 928.56M | 1.45B | 1.68B | 2.65B | 1.40B | 972.96M | 1.07B | 862.44M |
Depreciation & Amortization | 395.13M | 5.67M | 23.00M | 23.06M | 23.92M | 33.27M | 33.27M | 68.20M | 68.16M |